Scarica l'app Stockscreener
34.55
3.15%
-1.125
Pre-mercato:
34.69
0.14
+0.41%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché GMAB Giù?
Forum
Previsione
Frazionamento azionario
Genmab Adr Borsa (GMAB) Ultime notizie
Weekly Recap: Q4 2026 Phase III readouts and RSU/warrant grants - TradingView
Grant of Restricted Stock Units and Warrants to Employees in Genmab - GlobeNewswire Inc.
Genmab stock heads into the open after a 0.84 percent gain - AD HOC NEWS
symbol__ Stock Quote Price and Forecast - CNN
Genmab stock gains as Kempen raises target to DKK 3,300 - AD HOC NEWS
Genmab stock holds steady after first-half 2026 earnings update - AD HOC NEWS
Genmab stock gains as petosemtamab and Q2 figures draw focus - AD HOC NEWS
Genmab stock gains as petosemtamab Phase 3 start and strong Q2 figures support valuation - AD HOC NEWS
Genmab stock gains as HC Wainwright lifts Q3 earnings estimates and Phase 3 petosemtamab trial begin - AD HOC NEWS
Weekly Recap: Epcoritamab Phase III readout and DKK 44.3m share issuance - TradingView
ETFs Investing in Genmab A/S Sponsored ADR Stocks - TradingView
Genmab stock holds steady as analysts stick to a moderate buy view - AD HOC NEWS
Genmab A/S ADSADR Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Genmab stock holds in the mid-$30s as higher 2026 guidance leans on royalty income - ad-hoc-news.de
Genmab stock steadies as 2026 royalty-driven guidance lifts revenue outlook - AD HOC NEWS
Genmab stock holds steady as 2026 royalty-driven guidance is raised - ad-hoc-news.de
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Definitive Healthcare Corp (DH) and Atai Beckley N.V. (ATAI) - The Globe and Mail
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Legacy Wealth Asset Management LLC Grows Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Q2 Earnings Call Highlights - Yahoo Finance
Quantinno Capital Management LP Grows Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab (GMAB) Posts Perfect Technical and Setup Scores in Breakout Setup - ChartMill
SummitTX Capital L.P. Makes New Investment in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR $GMAB Shares Bought by Renaissance Technologies LLC - MarketBeat
Genmab/AbbVie lymphoma trial meets main goal, analyst eyes bigger market opportunity - MSN
Barometer Capital Management Inc. Boosts Holdings in Genmab A/S Sponsored ADR $GMAB - MarketBeat
What Makes Genmab A/S Sponsored ADR (GMAB) a Strong Momentum Stock: Buy Now? - MSN
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Diversify Wealth Management LLC Takes $1.22 Million Position in Genmab A/S Sponsored ADR $GMAB - marketbeat.com
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma - TradingView
GMABGenmab ADR Earnings - Finviz
H.C. Wainwright raises Genmab stock price target on trial success - Investing.com
Genmab (GMAB) Shows Modest Gains Amid Consolidation: Support and Resistance Levels in FocusFair Value Gap - dars.gov.et
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity - Sahm
Genmab opens the weekend with a clear strategy focus, shares hold their biotech range - Ad-hoc-news.de
Genmab A/S Sponsored ADR Actuals & Estimates (NASDAQ:GMAB) - TradingView
GE91 Forecast — Price Target — Prediction for 2027 - TradingView
GMAB1/N Forecast — Price Target — Prediction for 2027 - TradingView
GMAB News | GENMAB A/S -SP ADR (NASDAQ:GMAB) - ChartMill
Genmab A/S stock (DK0010272202): Copenhagen shares weaken as investors weigh outlook after updated A - AD HOC NEWS
GMAB Q1 2026 Earnings: EPS Misses Estimates by Over 40% as Stock DeclinesQuarterly Earnings Report - The Legal Advocate
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Crescent Biopharma (CBIO) and Genmab (GMAB) - The Globe and Mail
GMAB Stock Price, Quote & Chart | GENMAB A/S -SP ADR (NASDAQ:GMAB) - ChartMill
GMAB vs. ACAD: Which Stock Is the Better Value Option? - MSN
Genmab A/S stock (DK0010272202): earnings momentum and oncology pipeline keep investors watching - AD HOC NEWS
Genmab stock (DK0010272202): Analyst sentiment shifts as earnings forecasts decline - AD HOC NEWS
Genmab Earnings: Strong Patient Uptake and Diverse Late-Stage Pipeline Support Positive Outlook - Morningstar
1.48%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):